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Abstract It was recently shown that the conditioned media
(CM) of Human Umbilical Cord Perivascular Cells
(HUCPVCs), a mesenchymal progenitor population residing
within the Wharton Jelly of the umbilical cord, was able to
modulate in vitro the survival and viability of different neuro-
nal and glial cells populations. In the present work, we aimed
to assess if the secretome of HUCPVCs is able to 1) induce the
differentiation of human telencephalon neural precursor cells
(htNPCs) in vitro, and 2) modulate neural/glial proliferation,
differentiation and survival in the dentate gyrus (DG) of adult
rat hippocampus. For this purpose, two separate experimental
setups were performed: 1) htNPCs were incubated with
HUCPVCs-CM for 5 days after which neuronal differentia-
tion was assessed and, 2) HUCPVCs, or their respective CM,
were injected into the DG of young adult rats and their effects
assessed 7 days later. Results revealed that the secretome of
HUCPVCs was able to increase neuronal cell differentiation
in vitro; indeed, higher densities of immature (DCX+ cells)
and mature neurons (MAP-2+ cells) were observed when
htNPCs were incubated with the HUCPVCs-CM.
Additionally, when HUCPVCs and their CM were injected
in the DG, results revealed that both cells or CM were able to
increase the endogenous proliferation (BrdU+ cells) 7 days
after injection. It was also possible to observe an increased
number of newborn neurons (DCX+ cells), upon injection of
HUCPVCs or their respective CM. Finally western blot anal-
ysis revealed that after CM or HUCPVCs transplantation,
there was an increase of fibroblast growth factor-2 (FGF-2)
and, to a lesser extent, of nerve growth factor (NGF) in the DG
tissue. Concluding, our results have shown that the transplan-
tation of HUCPVCs or the administration of their secretome
were able to potentiate neuronal survival and differentiation
in vitro and in vivo.
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Introduction
It is well established that the mammalian adult brain has the
ability to generate new neurons [1]. In adult mammals, the
active neurogenic process occurs mainly in the subependymal
zone (SEZ) of the lateral ventricles and in the subgranular
zone (SGZ) of the hippocampal dentate gyrus (DG) [2, 3].
Nevertheless, the fact that adult neurogenesis is restricted to
specific brain regions implies a low regeneration capacity of
the central nervous system (CNS) [4]. Therefore, there has
been an increasing interest on the development of therapies to
promote CNS regeneration. Several studies have proposed the
use of adult stem cells as a possible tool for CNS regeneration,
and within it, mesenchymal stem cells (MSCs) [4–6] have
emerged as a promising therapeutic option [7–9]. In fact, over
the last decade, there has been a substantial effort to assess the
impact of MSCs for CNS repair [10–12]. Different studies
have demonstrated that bone-marrow (BM-MSCs) and adi-
pose stem cells (ASCs) produce a significant recovery of
neurological impairments in animal models of stroke [13,
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14], demyelination [15, 16], Parkinson’s disease (PD) [17, 18]
and spinal cord injury (SCI) [19, 20].
The stem/progenitors cells present in the Wharton Jelly of
the umbilical cord, known as Wharton Jelly Stem Cells (WJ-
MSCs) and Human Umbilical Cord Perivascular Cells
(HUCPVCs), have been suggested as possible populations of
interest for CNS applications [21–23]. Like BM-MSCs and
ASCs, these populations are also defined as MSCs [24–26].
They are plastic adherent, positive for MSCs’ markers (CD73,
CD90 and CD105), negative for hematopoietic markers
(CD45, CD34, CD14) and they also have the capacity to
differentiate towards osteogenic, chondrogenic, and adipogenic
lineages [25–27]. Concerning its application into the CNS,
Weiss and coworkers [28] revealed that MSCs isolated from
the bulk of the porcine WJ matrix, were able to survive in the
brains of rats after transplantation without concomitant immu-
nosuppressive therapy. In addition, it was also shown that these
stem cells were able to improve the condition of
hemiparkinsonian rats [28], to modulate the inflammatory
brain reaction after global ischemia [29] as well as, to poten-
tiate axonal regeneration on spinal cord injury (SCI) [30, 31].
However, little is known regarding the real mechanisms un-
derlying the interactions between umbilical cord stem cell
populations and the residing neuronal and glial cells.
Recently, it has been suggested that most of the effects that
may be promoted by these cells could be mediated by their
secretome [23, 32–34]. For instance, in a stroke model, Koh
et al. [35] and Ding et al. [36] showed that, after transplanta-
tion, MSCs were able to express granulocyte colony-
stimulating factor (G-CSF), vascular endothelial growth factor
(VEGF), glial-derived neurotrophic factor (GDNF), stem cell-
derived factor 1 (SDF-1) and brain-derived neurotrophic factor
(BNDF). Moreover, the authors considered that these growth
factors were the main mediatiors for the neuroprotection and
reduction of the lesion site as well as, for the improvement of
animal behavior and neuroplasticity [35]. Similar findings were
also reported in animal models of PD, demonstrating that after
cell transplantation there was an increase on the local tissue
expression of GDNF and fibroblast growth factor 20 (FGF-
20), leading to the protection of tyrosine hydroxylase (TH)
cells and to behavioral amelioration [28]. Adding to this, we
have recently shown that the secretome of these cells was able
to increase, in vitro, the survival of neuronal and glial popula-
tions through the secretion of different trophic factors and,
possibly, extracellular vesicles [33, 37]. Thus, based on these
results, we wanted to further explore if the secretome of
mesenchymal progenitors isolated from the Wharton Jelly
(HUCPVCs), would be able to: 1) induce neuronal differenti-
ation of human telencephalon neural progenitors (htNPCs) and
2) modulate phenomena such as neuronal/glial survival and
differentiation in the hippocampal neurogenic niche (DG),
upon an injection in the form of conditioned media (CM) or
after HUCPVCs transplantation.
Results revealed that the secretome of HUCPVCs was able
to induce neuronal differentiation of htNPCs in vitro.
Moreover, animals that were injected with the secretome of
the cells under study into the hippocampal DG, displayed
similar levels of proliferation, neuronal/glial survival and dif-
ferentiation comparing to those transplanted with HUCPVCs.
Finally the injection of the secretome also lead to an enhanced
expression of FGF-2 in the resident DG.
Materials and Methods
Cell Culture
Isolation and Primary Culture of Human Umbilical Cord
Perivascular Stem Cells (HUCPVCs)
HUCPVCs were obtained from Prof. John E. Davies (University
of Toronto, Toronto Canada). Cells were isolated from umbilical
cords collected after c-section, with the consent of parenting
entities. The isolation of HUCPVCs was performed based on
the protocol established by Sarugaser et al. [27]. Briefly, the
umbilical cord was cut into small segments (4–5 cm) to expose
both arteries and vein, rejecting the epithelium. Once isolated the
vessels, with a sterilized suture, the ends of the vessels were fixed
creating a short loop in order to reduce the contamination by
erythrocytes. Vessels were then placed in a collagenase solution
(0.5 mg/ml for arteries and 0.75 mg/ml for veins; Sigma, USA)
and incubated at 37 °C for a period of 16–18 h. Completed this
period, the vessels were removed from the suspension and
diluted in PBS without Mg2+/Ca2+ (Invitrogen, USA). Finally,
HUCPVCs were ressuspended in Alpha-Mem medium
(Invitrogen, USA) supplemented with 1 % of antibiotic/
antimycotic (Invitrogen, USA) and 10 % of fetal bovine serum
(FBS) (Invitrogen, USA), and plated on culture at a density of
4.0×103 cells/cm2. Subsequently, the culture medium was
renewed every 3 days and the culture maintained at 37 °C, 5 %
CO2, 95 % air and 90 % relative humidity until confluence.
Mesenchymal phenotype of HUCPVCs was screened by
differentiating them towards osteogenic and adipogenic lineages.
Cells were incubated with Mesencult® MSC Basal medium
supplemented with Mesencult® adipogenic stimulatory supple-
ments or Mesencult® osteogenic kit (Stem Cell Technologies,
Canada) during 2 weeks. At the end of this period, osteogenic
differentiation was assessed through Alizarin Red staining
(Sigma, USA), while adipogenic differentiation was assessed
through Oil Red O staining (Sigma, USA).
HUCPVCs Conditioned Media (HUCPVCs-CM) Collection
The conditioned media (CM) used was collected from
HUCPVCs cultures in passage five (P5) previously plated
and kept at a density of 4.0×103 cells/cm2 for 3 days in
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Alpha-Mem medium (Invitrogen, USA) supplemented with
1 % of antibiotic/antimycotic (Invitrogen, USA) and 10 %
FBS (Invitrogen, USA). After this, the flasks were washed
three times in Neurobasal A medium (Invitrogen, USA) for
5 min and then, washed five times in PBS without Mg2+/Ca2+
(Invitrogen, USA). Following this Neurobasal A medium
supplemented with kanamycin (1 %) (Invitrogen, USA) was
added to the cells. After 24 h the conditioned media (CM) was
collected and frozen at −80 °C until use.
Primary Culture of Human Telencephalon Neural
Progenitors (htNPCs) and Incubation with HUCPVCs-CM
htNPCs were obtained from Prof. Leo A. Behie (University of
Calgary, Calgary, Canada). Cells were isolated from the telen-
cephalon region according with the protocols and strict ethical
guidelines previously established [38–40]. htNPCs were thawed
at 37 °C and the content placed in a T-25 flask (Nalge Nunc,
Rochester, NY) containing 5mL of a serum-free medium PPRF-
h2 [38]. After 2 days, the cells were harvested and mechanically
dissociated into a single cell suspension, and subcultured into
fresh cell growth medium (PPRF-h2). Every 4 days, the T-flaks
were fed by replacing 40 % of the spent medium with fresh
growth medium. After 14–20 days of growth in the culture
flasks, htNPCs were passaged and plated on a pre-coated
(poly-D-lysine hydrobromide (100 μg/mL) and laminin
(10 μg/mL) - Sigma, USA) 24-well plate at a density of 1.0×
105 per well during 5 days with the HUCPVCs-CM at 37 °C,
5 % CO2, 95 % air and 90 % relative humidity. Neurobasal A
medium with 1 % of kanamycin was used as control group.
Stereotaxic Surgeries
All experiments were conducted using 8 weeks old male Wistar
rats (Charles River, Spain). Consent from the Portuguese national
authority for animal experimentation, Direção Geral de
Veterinária (ID: DGV9457), was obtained before the experi-
ments. Animals were kept and handled in accordance with the
guidelines for the care and handling of laboratory animals in the
Directive 2010/63/EU of the European Parliament and of the
Council. The animals were housed and maintained in a con-
trolled environment at 22–24 °C and 55 % humidity, on 12 h
light/dark cycles and fed with regular rodent’s chow and tap
water ad libitum. Animals were handled for 1 week prior to the
beginning of the injections, in order to reduce the stress induced
by the surgical procedures. For the cerebral injections three
experimental groups were used (n=5/group): 1) Sham, 2)
HUCPVCs and 3) HUCPVCs-CM. Adult rats were anesthetized
with ketamine hydrochloride (150 mg/kg) plus medetomidine
(0.3 mg/kg). Using a stereotaxic system (Stoelting, USA) and a
Hamilton syringe (0.5 μl Hamilton, Switzerland) all injections
made in these three groups were bilateral according to previously
determined coordinates (Anterior/Posterior (AP)= 3.5 mm;
Dorsal/Ventral (DV)=3.5/3.1 mm; Lateral (L)= 2.0 mm) [41].
Coordinates had been previously confirmed by a preliminary
surgery with methylene blue injected into the desired area (data
not shown). The volume injected per DG was 0.5 μl with a rate
of injection of 0.25 μl per minute. Two minutes were allowed
after each injection in order to avoid any backflow up the needle
tract. Sham group was only injected with 0.5 μl of Neurobasal A
medium; HUCPVCs group with 5.0×104 cells (in 0.5 μl of
Neurobasal A medium) and finally, the CM group were injected
with 0.5 μl of HUCPVCs-CM. At the end, the animals were
sutured and then injected with 100 μl of anti-sedating (Orion
Pharma, Finland) in order to recover from surgical procedure.
BrdU Administration and Histological Procedures
Adult rats received intraperitoneally (i.p.) 100 mg/kg of BrdU
(Sigma, USA) 24 h before the sacrifice. 7 days after of the
stereotaxic injection animals were anaesthetized with sodium
pentobarbital (Eutasil, 60 mg/kg i.p.; Ceva Saúde Animal,
Portugal) and perfused with paraformaldehyde (4 %)
(Merck, Lisbon, Portugal) diluted in PBS (0,1x) in order to
fix the tissues. Subsequently, the brains were stored in sucrose
solution (30 %) before heading to histological processing.
Immunostaining
htNPCs were fixed in 4 % paraformaldehyde for 15 min, and
then permeabilized by incubation with 0.1 % Triton X-100 in
PBS for 5 min at room temperature, and washed three times in
PBS. hNPCs were then blocked with 10 % of fetal calf serum
(FCS, Invitrogen, USA) in PBS, being followed by a 1 h
incubation (at room temperature) with the primary antibodies:
rabbit anti-doublecortin (DCX; 1:500, Abcam, USA) to detect
immature neurons and mouse anti-rat microtubule associated
protein-2 (MAP-2; 1:500, Sigma, USA) to detect mature neu-
rons. htNPCs were then washed in PBS three times and incu-
bated with the secondary antibodies namely, Alexa Fluor 488
goat anti-rabbit (IgG, Invitrogen, USA) and Alexa Fluor 594
goat anti-mouse immunoglobulin G (IgG; Invitrogen) during
1 h at room temperature. Finally a 10 min incubation with 4-6-
diamidino-2-phenylindole-dihydrochloride (DAPI; Invitrogen,
USA) was performed. Samples were then observed under an
Olympus BX-61 Fluorescence Microscope (Olympus,
Germany). For this purpose, three coverslips and ten represen-
tative fields per condition were chosen and analyzed. Results
are shown as percentage of DCX or MAP-2 positive cells over
the total number of cells per field of observation (n=3).
Regarding the in vivo experiment, coronal sections were
obtained by vibrotome (VT1000S, Leica, Germany) with a thick-
ness of 40 μm and processed as free-floating sections. As first
approach, sections were permeabilized in PBS-T (0.2 %) (three
times for 10 min), and were subsequently incubated with 10 %
FCS/PBS during 2 h for endogenous blocking. After that,
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sectionswere incubated overnight at 4 °Cwith primary antibodies
namely, DCX (1:300) for immature neurons, rabbit anti-rat glial
fibrillary acid protein (GFAP; 1:200 Millipore, USA) for astro-
cytes detection;Human nuclear antigen (HNA; 1:100, Millipore,
USA) for HUCPVCs detection; and 5bromo-2-deoxyuridine
(BrdU; 1:100, Abcam,USA) for proliferation. Sections were then
incubated with secondary antibodies: Alexa Fluor 568 goat anti-
mouse immunoglobulin G (IgG; Invitrogen, USA), Alexa Fluor
488 goat anti-rabbit (IgG, Invitrogen, USA) during 2 h at room
temperature, followed by a 10min incubationwithDAPI. Images
were obtained with a confocal microscope (Olympus FV1000,
Germany) using the software FV10-ASW 2.0c (Olympus,
Germany), presenting the hippocampal DG (five sections per
animal were analyzed for a n=5/group). Then, SGZ/GCL area
was defined and the cell counts were made in these areas.
Western Blot
Rat hippocampi (n=4/group) were homogenized in cold RIPA
buffer (50 mMTris–HCl, 150 mMNaCl, 0.1 % SDS, 1%NP-
40, PMSF and a protease inhibitors cocktail (Complete;
Roche). Protein concentration was determined using the
Bradford assay (BioRad). Samples were sonicated for 5 min,
boiled for 5 min at 100 °C, and centrifuged for 10 s before
loading. Fifty micrograms of total protein were loaded into
15 % SDS-Page gels and then transferred to nitrocellulose
membranes. After overnight incubation at 4 °C with the
primary antibodies: rabbit anti-FGF2 (1:100, Abcam), rabbit
anti-NGF (1:100, Abcam), the secondary antibodies were
incubated 1 h at room temperature at the following dilutions:
anti-rabbit (1:10.000, BioRad) and anti-mouse (1:15.000,
BioRad). Antibody affinity was detected by chemilumines-
cence (ECL kit, BioRad). Band quantification was performed
using ImageJ software according to the manufacturer’s in-
structions using alpha-tubulin as the loading control.
Statistical Analysis
Statistical evaluation was performed using One-way ANOVA
and Student’s t-test through the program GraphPad Prism five
(GraphPad Software Inc., La Jolla, CA, USA). Data is pre-
sented as mean ± standard deviation. Significance value was
set at p<0.05.
Results
Characterization of HUCPVCs
The isolation of HUCPVCs from the perivascular region of
the human umbilical cord has previously been reported [27].
In the present study, it was possible to observe HUCPVCs in
culture, presenting the morphological characteristics typical of
MSCs (Fig. 1a). The differentiation into mesodermal lineages
is considered another basic characteristic of MSCs [42, 43].
We were also able to observe the multipotent character of
HUCPVCs, obtained through the differentiation towards the
osteogenic (Fig. 1b, formation of bone nodules) and
adipogenic (Fig. 1c, formation of fat droplets) lineages.
These results confirm that HUCPVCs are capable to differen-
tiate into different lineages similarly to otherMSC populations
[26, 44, 45].
HUCPVCs-CM Induced Neuronal Differentiation of hNPCs
in vitro
htNPCs grow as neurospheres in a serum-free medium, PPRF-
h2 (Fig. 2a). However, when the growth medium is removed
and replaced by the HUCPVCs-CM or Neurobasal A medi-
um, htNPCs lose the neurosphere state and start to differenti-
ate (Fig. 2b). Immunocytochemistry analysis revealed that
when htNPCs were incubated for 5 days with the
HUCPVCs-CM there was a clear increase (p<0.01) of DCX
positive (immature neurons; Fig. 3b/c) and MAP-2 positive
cells (mature neurons; Fig. 3e/f) densities when compared to
control group (incubation with Neurobasal A medium), as the
latter had almost undetected numbers of DCX and MAP-2
positive cells (Fig. 3a/d).
Fig. 1 Multipotent character of HUCPVCs in vitro. (a) HUCPVCs under
standard culturing conditions, and differentiated into (b) osteogenic and
(c) adipogenic lineages. Osteogenic differentiation was assessed using
Alizarin Red staining, while adipogenic phenotype was assessed through
the use of Oil Red O staining (Scale bar: (a) 100 μm, (b, c) 50 μm)
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HUCPVCs and their CM Promoted Proliferation
and Differentiation of Endogenous Progenitor Cells
To assess their role in vivo HUCPVCs (50.000 cells/
DG) and HUCPVCs-CM (0.5 μL/DG) were bilaterally
injected into the hippocampal DG of adult rats without
any concomitant immunosuppression therapy. As a first
approach, we determined if HUCPVCs were able to
survive into the DG 7 days after the transplantation.
As it can be observed in Fig. 4a, the transplanted cells
detected by immunostaining for human nuclear antigen
(HNA), were able to survive in the DG 7 days after the
transplantation.
In order to confirm proliferation and the cell type of
the newly-born cells in the hippocampal DG, sections
were immunostained with different markers. BrdU-
positive cells were found mainly in the SGZ of the
hippocampus. We first verified if the proliferating cells
could be derived from HUCPVCs, but no positive co-
labeling between BrdU and HNA was observed
(Fig. 4b). Nevertheless, the analysis of the cell prolifer-
ation in the DG, revealed a significant increase in the
number of BrdU+ cells within the HUCPVCs-injected
DG (p<0.05; Fig. 4c) when compared to the control
group (Sham, Fig. 4c). Similar findings were observed
in the group injected with HUCPVCs-CM, (p<0.05,
Fig. 4c).
After observing that HUCPVCs and their respective CM
were able to stimulate the proliferation in the DG, we next
aimed to determine their effects on the differentiation of DG
Fig. 2 Expansion of Human
Telencephalon Neural Precursor
Cells (htNPCs) in vitro. a htNPCs
standard expansion as
neurospheres in the presence of
their growth medium PPRF-h2
and b) spontaneous
differentiation into neural
phenotypes upon PPRF-h2
removal. (Scale bar: 50 μm)
Fig. 3 In vitro neuronal differentiation of htNPCs. HUCPVCs-CM was
able to significantly increase the survival and differentiation of htNPCs
into neuronal phenotypes such as (b) immature (DCX+cells) and (e)
mature (MAP-2+ cells) neurons when compared to control conditions
(a/d) (c/f, mean ± SD, n=3, p<0.05). CT Control (Neurobasal A media),
HU-CM (HUCPVCs conditioned media). (Scale bar: 50 μm)
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resident cells. 7 days post-injection it was observed that
both HUCPVCs (Fig. 5b) and their CM (Fig. 5c) were
able to increase (p<0.05) the number of DCX-
expressing cells in the SGZ (Fig. 5d) when compared
to the Sham group (Figs. 5a); for the GCL, differences
were only observed between HUCPVCs-CM and sham
groups, respectively (Fig. 5e, p<0.05). Regarding the
effects on the astrocytic cell densities (Fig. 6a-c), dif-
ferences were only observed (p < 0.05) for the
HUCPVCs-CM group in the SGZ (Fig. 6d). No differ-
ences were observed in the GCL.
Expression of Trophic Factors
after HUCPVCs/HUCPVCs-CM Transplantation or Injection
In order to stimulate the endogenous proliferation as well as to
increase the number of neuronal/glial cell populations,
HUCPVCs or their CM must be able to modulate the sur-
rounding environment through direct interaction or paracrine
action [45]. Therefore the levels of FGF-2 and NGF in the DG
were determined. Western blot analysis (Fig. 7) revealed that
levels of FGF-2 were significantly increased when compared
to those obtained by the Sham group (p<0.05; Figs. 7a/b).
Fig. 4 Transplantation of HUCPVCs and their CM into the hippocampal
DG. HUCPVCs were able to survive in vivo 7 days after transplantation
(HNA+ cells, red) (a). However, they were not proliferating, as there was
no co-localization between HNA+ and BrdU+ cells. Cell counts (c)
revealed that 7 days post-injection both HUCPVCs and CM transplanted
groups were able to increase the number of BrdU-labeled cells in the DG,
when compared to control (Sham group; mean ± SD, n=5, p<0.05). SH
(Sham), HU (HUCPVCs), HU-CM (HUCPVCs conditioned media).
(Scale bar: 100 μm)
Fig. 5 HUCPVCs-CM enhances neuronal densities in the DG of
hippocampus. Immunohistochemistry for DCX (newborn neurons: a/b/
c) revealed that the CM of HUCPVCs was able to increase the number of
newborn neurons (c, statistically significant to the Sham group; mean ±
SD, n=5, p<0.05) both in the (d) SGZ and (e) GCL. HUCPVCs were
also able to increase the number of immature neurons (B, statistically
significant to the Sham group; mean ± SD, n=5, p<0.05) into the (d)
SGZ. SH (Sham), HU (HUCPVCs), HU-CM (HUCPVCs conditioned
media). (Scale bar: 100 μm)
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Discussion
The use of MSCs-based therapies as a new strategy for CNS
regeneration constitutes one of the biggest challenges for
regenerative medicine. Different reports have shown that the
release of paracrine factors and extracellular vesicles is the
main route by which MSCs can mediate improvements in the
CNS [34]. Within the different MSCs based populations,
HUCPVCs have been described as an attractive and readily
available alternative source of MSCs for cell therapy [27].
Indeed, studies have shown that HUCPVCs have a higher
clonogenic frequency and display a robust self-renewing ca-
pacity. Additionally, they have also shown to possess
multilineage differentiation [46, 47], as confirmed in the pres-
ent report (Fig. 1). Moreover, previous results from our labo-
ratory revealed that the secretome of these cells was able to
induce and increase the cell survival and densities of different
(hippocampal, cortical and cerebellar) neuronal and glial cells
[23, 33, 37, 48]. The initial in vitro experiments performed in
the present report revealed that the secretome of HUCPVCs
could also modulate the differentiation of CNS derived cells.
Indeed, as shown in Fig. 3 when htNPCs were incubated with
HUCPVCs-CM an increased differentiation of htNPCs into
neuronal lineages (immature (DCX+) and mature (MAP-2+)
neurons) was observed. Previous work fromRibeiro et al. [33]
had already shown that these cells have a strong expression of
NGF, which is most likely playing a strong role on the ob-
served effects.
In vivo experiments revealed that HUCPVCs were able to
boost cell proliferation within the DG 7 days after injection, as
assessed by the number of BrdU+ cells (Fig. 4c). Similar
outcomes were reported by Munoz and colleagues [49] after
Fig. 6 HUCPVCs-CM enhances astrocytic densities in the DG of
hippocampus. Immunohistochemistry to GFAP (Astrocytes: a/b/c)
revealed increased numbers promoted by the injection of HUCPVCs-
CM (c, statistically significant to the Sham group; mean ± SD, n=5,
p<0.05) in the (d) SGZ. In the (e) GCL no differences were observed
7 days post-injection. SH (Sham),HU (HUCPVCs),HU-CM (HUCPVCs
conditioned media) (Scale bar: 100 μm)
Fig. 7 Injection of HUCPVCs-CM increased the expression of neuro-
trophic factors in vivo. By Western blot it was possible to observe that
HUCPVCs-CMwas able to increase the secretion of (a) FGF-2 in the DG
tissue (b, statistically significant to the Sham group; mean ± SD, n=4,
p<0.05). It was also observed a slightly increase in the levels of (c) NGF,
although no statistically significant differences were observed when
compared to the Sham group. SH (Sham), HU (HUCPVCs), HU-CM
(HUCPVCs conditioned media)
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BM-MSCs transplantation in the DG, being this finding at-
tributed to the secretion of growth factors and chemokines;
this hypothesis was, in fact, confirmed in the present study.
Indeed, as shown in Fig. 4c, the application of CM discloses
similar levels of cell proliferation to those obtained by the cell
transplanted group. This is a strong indicator that the
secretome, per se, regulates such phenomena.
Similar effects were also observed regarding neuronal dif-
ferentiation. Indeed, 7 days after injection of HUCPVCs, or
their respective CM, it was possible to observe a significantly
increase number of immature neurons (DCX+ cells) in the
SGZ (Fig. 5d). This is in line with the findings of Tfilin and
colleagues [50], who transplanted BM-MSCs into the hippo-
campal DG, and observed that after the transplantation there
were increasing numbers of DCX-expressing cells, indicating
the differentiation of newly formed neurons. Curiously, in the
present study it was observed, that the CM, and not the cells,
was also able to increase significantly the number of DCX-
expressing cells into the GCL (Fig. 5e), suggesting that the
secretome could stimulate the migration of these newly-born
neurons within the DG. We hypothesized that these effects are
related with the increased expression of FGF-2 in the CM
injected group (Fig. 7a/b). Indeed, the latter is considered to be
a potent modulator of the early phases of neurogenesis, being
able to support not only the proliferation as well as, to enhance
the survival and neuronal/glial maturation [45, 50]. The small
increase of NGF in the DG tissue (Fig. 7a/c) could also impact
on these phenomena [49, 51–53]. Nevertheless, although pro-
teomic studies are still scarce to explain the functional effects
of MSCs secretome (including that of HUCPVCs as well),
previous studies from our group have revealed, through the
use of targeted and non-targeted proteomic-based techniques,
the presence of important molecules for CNS physiology,
within it [33, 37]. For instance, Ribeiro and colleagues [33]
demonstrated that HUCPVCs were able to robustly secrete
NGF, an important neurotrophin for the support of neuronal/
glial cell survival [51, 52]. In a subsequent study, it was also
possible to observe that HUCPVCs were also able to secrete
important intracellular proteins such as 14-3-3, Hsp70 and
UCHL1, which are known for their important roles in the
induction of cell proliferation, survival and differentiation,
including in cells derived from the CNS [54–56].
Therefore it is possible that these molecules are playing a
role on the phenomena exerted in vivo by HUCPVCs
secretome.
Conclusions
In the present work it was demonstrated that the secretome of
HUCPVCs, aMSC based populationwithin theWharton Jelly
of the umbilical cord, was able to induce neuronal differenti-
ation of human neural progenitors into neurons in different
stages of maturation. Additionally, in vivo injections into the
hippocampal DG, a known neurogenic niche, revealed that
both HUCPVCs or CM injected groups, had increased levels
of BrdU+ cells (proliferation) and newly differentiated neu-
rons (DCX+), when compared to sham animals. These out-
comes can be associated with the expression of FGF-2 and
other proteins, which have been previously shown to consti-
tute part of the secretome of these cells. These results suggest
that the secretome (alone) of a MSC-like population is able to
modulate neural progenitor proliferation and differentiation,
which may open new therapeutic opportunities in the future.
Acknowledgments Foundation Calouste Gulbenkian for funds under
the scope of the Gulbenkian Programme to Support Cutting Edge Re-
search in Life Sciences; Portuguese Foundation for Science and Technol-
ogy (FCT) for Ciência 2007 program and IF Development Grant (A.J.
Salgado), and pre-doctoral fellowship to F.G. Teixeira (SFRH / BD /
69637 / 2010); John E. Davies for kindly providing the HUCPVCs used
in this work.
Conflict of Interest The author(s) declare that they have no competing
interests.
References
1. Balu, D. T., & Lucki, I. (2009). Adult hippocampal neurogenesis:
regulation, functional implications, and contribution to disease pa-
thology. Neuroscience and Biobehavioral Reviews, 33(3), 232–52.
2. Kazanis, I. (2009). The subependymal zone neurogenic niche: a
beating heart in the centre of the brain: how plastic is adult
neurogenesis? Opportunities for therapy and questions to be ad-
dressed. Brain, 132(Pt 11), 2909–21.
3. Kazanis, I., Belhad, I. A., Faissner, A., & Ffrench-Constant, C.
(2007). The adult mouse subependymal zone regenerates efficiently
in the absence of tenascin-C. Journal of Neuroscience, 27(51),
13991–6.
4. Kan, I., Barhum, Y., Melamed, E., & Offen, D. (2011). Mesenchymal
stem cells stimulate endogenous neurogenesis in the subventricular
zone of adult mice. Stem Cell Reviews, 7(2), 404–12.
5. Lindvall, O., & Kokaia, Z. (2010). Stem cells in human neurodegen-
erative disorders–time for clinical translation? Journal of Clinical
Investigation, 120(1), 29–40.
6. Shihabuddin, L. S., & Aubert, I. (2010). Stem cell transplantation for
n e u r ome t a b o l i c a n d n e u r o d e g e n e r a t i v e d i s e a s e s .
Neuropharmacology, 58(6), 845–54.
7. Pittenger, M. F.,Mackay, A.M., Beck, S. C., Jaiswai, R. K., Douglas,
R., Mosca, J. D., et al. (1999). Multilineage potential of adult human
mesenchymal stem cells. Science, 284(5411), 143–7.
8. Zuk, P. A., Zhu, M., Ashjian, P., De Ugarte, D. A., Huang, J. I.,
Mizuno, H., et al. (2002). Human adipose tissue is a source of
multipotent stem cells. Molecular Biology of the Cell, 13(12),
4279–95.
9. Wang, H. S., Hung, S. C., Peng, S. T., Huang, C. C.,Wei, H.M., Guo,
Y. J., et al. (2004). Mesenchymal stem cells in the Wharton’s jelly of
the human umbilical cord. Stem Cells, 22(7), 1330–7.
10. Daher, S. R., Johnstone, B. H., Phinney, D. G., & March, K. L.
(2004). Adipose stromal/stem cells: basic and translational advances:
the IFATS collection. Stem Cells, 26(10), 2664–5.
Stem Cell Rev and Rep (2015) 11:288–297 295
Author's personal copy
11. Phinney, D. G., & Isakova, I. (2005). Plasticity and therapeutic
potential of mesenchymal stem cells in the nervous system. Current
Pharmaceutical Design, 11(10), 1255–65.
12. Prockop, D. J., Azizi, S. A., Colter, D., Digirolamo, C., Kopen, G., &
Phinney, D. G. (2000). Potential use of stem cells from bone marrow
to repair the extracellular matrix and the central nervous system.
Biochemical Society Transactions, 28(4), 341–5.
13. Wei, X., Zhao, L., Zhong, J., Gu, H., Feng, D., Johnstone, B. H., et al.
(2009). Adipose stromal cells-secreted neuroprotective media against
neuronal apoptosis. Neuroscience Letters, 462(1), 76–9.
14. Honmou, O., Onodera, R., Sasaki, M., Waxman, S. G., & Kocsis, J.
D. (2012). Mesenchymal stem cells: therapeutic outlook for stroke.
Trends in Molecular Medicine, 18(5), 292–7.
15. Constantin, G., Marconi, S., Rossi, B., Angiari, S., Anghileri, E.,
Gini, B., et al. (2009). Adipose-derived mesenchymal stem cells
ameliorate chronic experimental autoimmune encephalomyelitis.
Stem Cells, 27(10), 2624–35.
16. Cristofanilli, M., Harris, V. K., Zigelbaum, A., Goossens, A. M., Lu,
A., Rosenthal, H., et al. (2011). Mesenchymal stem cells enhance the
engraftment and myelinating ability of allogeneic oligodendrocyte
progenitors in dysmyelinated mice. Stem Cells and Development,
20(12), 2065–76.
17. Cova, L., Armentero, M. T., Zennaro, E., Calzarossa, C., Bossolasco,
P., Busca, G., et al. (2010). Multiple neurogenic and neurorescue
effects of human mesenchymal stem cell after transplantation in an
experimental model of Parkinson’s disease. Brain Research, 1311,
12–27.
18. Erba, P., Terenghi, G., &Kingham, P. J. (2010). Neural differentiation
and therapeutic potential of adipose tissue derived stem cells.Current
Stem Cell Research & Therapy, 5(2), 153–60.
19. Arboleda, D., Forostyak, S., Jendelova, P., Marekova, D., Amemori,
T., Pivonkova, H., et al. (2011). Transplantation of predifferentiated
adipose-derived stromal cells for the treatment of spinal cord injury.
Cellular and Molecular Neurobiology, 31(7), 1113–22.
20. Park, J. H., Kim, D. Y., Sung, I. Y., Choi, G. H., Jeon, M. H., Kim, K.
K., et al. (2012). Long-term results of spinal cord injury therapy using
mesenchymal stem cells derived from bone marrow in humans.
Neurosurgery, 70(5), 1238–47. discussion 1247.
21. Taghizadeh, R. R., Cetrulo, K. J., & Cetrulo, C. L. (2011). Wharton’s
Jelly stem cells: future clinical applications. Placenta, 32(Suppl 4),
S311–5.
22. Datta, I., Mishra, S., Mohanty, L., Pulikkot, S., & Joshi, P. G. (2011).
Neuronal plasticity of human Wharton’s jelly mesenchymal stromal
cells to the dopaminergic cell type compared with human bone
marrow mesenchymal stromal cells. Cytotherapy, 13(8), 918–32.
23. Salgado, A. J., Fraga, J. S., Mesquita, A. R., Neves, N. M., Reis, R.
L., & Sousa, N. (2010). Role of human umbilical cord mesenchymal
progenitors conditioned media in neuronal/glial cell densities, viabil-
ity, and proliferation. Stem Cells and Development, 19(7), 1067–74.
24. Weiss, M. L., & Troyer, D. L. (2006). Stem cells in the umbilical
cord. Stem Cell Reviews, 2(2), 155–62.
25. Sarugaser, R., Ennis, J., Stanford, W. L., & Davies, J. E. (2009).
Isolation, propagation, and characterization of human umbilical cord
perivascular cells (HUCPVCs). Methods in Molecular Biology, 482,
269–79.
26. Baksh, D., Yao, R., & Tuan, R. S. (2007). Comparison of prolifera-
tive and multilineage differentiation potential of human mesenchy-
mal stem cells derived from umbilical cord and bone marrow. Stem
Cells, 25(6), 1384–92.
27. Sarugaser, R., Lickorish, D., Baksh, D., Hosseini, M. M., & Davies,
J. E. (2005). Human umbilical cord perivascular (HUCPV) cells: a
source of mesenchymal progenitors. Stem Cells, 23(2), 220–9.
28. Weiss, M. L., Medicetty, S., Bledsoe, A. R., Rachakatia, R. S., Choi,
M., Merchav, S., et al. (2006). Human umbilical cord matrix stem
cells: preliminary characterization and effect of transplantation in a
rodent model of Parkinson’s disease. Stem Cells, 24(3), 781–92.
29. Hirko, A. C., Dallasen, R., Jomura, S., & Xu, Y. (2008). Modulation
of inflammatory responses after global ischemia by transplanted
umbilical cord matrix stem cells. Stem Cells, 26(11), 2893–901.
30. Yang, C. C., Shih, Y. H., Ko,M. H., Hsu, S. Y., Cheng, H., & Fu, Y. S.
(2008). Transplantation of human umbilical mesenchymal stem cells
fromWharton’s jelly after complete transection of the rat spinal cord.
PloS One, 3(10), e3336.
31. Zhang, L., Zhang, H. T., Hong, S. Q., Ma, X., Jiang, X. D., & Xu, R.
X. (2009). Cografted Wharton’s jelly cells-derived neurospheres and
BDNF promote functional recovery after rat spinal cord transection.
Neurochemical Research, 34(11), 2030–9.
32. Carvalho, M. M., Teixeira, F. G., Reis, R. L., Sousa, N., & Salgado,
A. J. (2011). Mesenchymal stem cells in the umbilical cord: pheno-
typic characterization, secretome and applications in central nervous
system regenerative medicine. Current Stem Cell Research &
Therapy, 6(3), 221–8.
33. Ribeiro, C. A., Fraga, J. S., Graos, M., Neves, N. M., Reis, R. L.,
Gimble, J.M., et al. (2012). The secretome of stem cells isolated from
the adipose tissue and Wharton jelly acts differently on central
nervous system derived cell populations. Stem Cell Research &
Therapy, 3(3), 18.
34. Teixeira, F. G., Carvalho, M. M., Sousa, N., & Salgado, A. J. (2013).
Mesenchymal stem cells secretome: a new paradigm for central
nervous system regeneration? Cellular and Molecular Life
Sciences, 70(20), 3871–82.
35. Koh, S. H., Kim, K. S., Choi, M. R., Jung, K. H., Park, K. S., Chai, Y.
G., et al. (2008). Implantation of human umbilical cord-derived
mesenchymal stem cells as a neuroprotective therapy for ischemic
stroke in rats. Brain Research, 1229, 233–48.
36. Ding, D. C., Shyu, W. C., Chiang, M. F., Lin, S. Z., Chang, Y. C.,
Wang, H. J., et al. (2007). Enhancement of neuroplasticity through
upregulation of beta1-integrin in human umbilical cord-derived stro-
mal cell implanted stroke model. Neurobiology of Disease, 27(3),
339–53.
37. Fraga, J. S., Silva, N. A., Lourenço, A. S., Gonçalves, V., Neves, N.
M., Reis, R. L., et al. (2013). Unveiling the effects of the secretome of
mesenchymal progenitors from the umbilical cord in different neu-
ronal cell populations. Biochimie, 95(12), 2297–303.
38. Baghbaderani, B. A., Mukhida, K., Sen, A., Kallos, M. S., Hong, M.,
Mendez, I., et al. (2010). Bioreactor expansion of human neural
precursor cells in serum-free media retains neurogenic potential.
Biotechnology and Bioengineering, 105(4), 823–33.
39. Mendez, I., Dagher, A., Hong, M., Gaudet, P., Weerasinghe, S.,
McAlister, V., et al. (2002). Simultaneous intrastriatal and intranigral
fetal dopaminergic grafts in patients with Parkinson disease: a pilot
study. Report of three cases. Journal of Neurosurgery, 96(3), 589–96.
40. Mendez, I., Sanchez-Pernaute, R., Cooper, O., Vinuela, A., Ferrari, D.,
Bjorklund, L., et al. (2005). Cell type analysis of functional fetal dopa-
mine cell suspension transplants in the striatum and substantia nigra of
patients with Parkinson’s disease. Brain, 128(Pt 7), 1498–510.
41. Paxinos, G., & Watson, C. (2004). Rat brain in stereotaxic
coordinates (5th ed.). San Diego: Academic.
42. Bernardo, M. E., Locatelli, F., & Fibbe, W. E. (2009). Mesenchymal
stromal cells. Annals of the New York Academy of Sciences, 1176,
101–17.
43. Chen, Y., Shao, J. Z., Xiang, L. X., Dong, X. J., & Zhang, G. R.
(2008). Mesenchymal stem cells: a promising candidate in regener-
ative medicine. International Journal of Biochemistry and Cell
Biology, 40(5), 815–20.
44. Baer, P.C. and Geiger, H. (2012). Adipose-derived mesenchymal
stromal/stem cells: tissue localization, characterization, and hetero-
geneity. Stem Cells International, p. 812693.
45. Huang, A. H., Snyder, B. R., Cheng, P. H., & Chan, A. W. (2008).
Putative dental pulp-derived stem/stromal cells promote proliferation
and differentiation of endogenous neural cells in the hippocampus of
mice. Stem Cells, 26(10), 2654–63.
296 Stem Cell Rev and Rep (2015) 11:288–297
Author's personal copy
46. Sarugaser, R., Hanoun, L., Keating, A., Stanford,W. L., & Davies, E.
(2009). Human mesenchymal stem cells self-renew and differentiate
according to a deterministic hierarchy. PloS One, 4(8), e6498.
47. Yannarelli, G., Pacienza, N., Cuniberti, L., Medin, J., Davies, J., &
Keating, A. (2013). Brief report: the potential role of epigenetics on
multipotent cell differentiation capacity of mesenchymal stromal
cells. Stem Cells, 31(1), 215–20.
48. Ribeiro, C. A., Salgado, A. J., Fraga, J. S., Silva, N. A., Reis, R. L., &
Sousa, N. (2011). The secretome of bone marrow mesenchymal stem
cells-conditioned media varies with time and drives a distinct effect
on mature neurons and glial cells (primary cultures). Journal of
Tissue Engineering and Regenerative Medicine, 5(8), 668–72.
49. Munoz, J. R., Stoutenger, B. R., Robinson, A. P., Spees, J. L., &
Prockop, D. J. (2005). Human stem/progenitor cells from bone
marrow promote neurogenesis of endogenous neural stem cells in
the hippocampus of mice. Proceedings of the National Academy of
Sciences of the United States of America, 102(50), 18171–6.
50. Tfilin, M., Sudai, E., Merenlender, A., Gispan, I., Yadid, G., &
Turgeman, G. (2010).Mesenchymal stem cells increase hippocampal
neurogenesis and counteract depressive-like behavior. Molecular
Psychiatry, 15(12), 1164–75.
51. Frielingsdorf, H., Simpson, D., Thal, L. J., & Pizzo, D. P. (2007).
Nerve growth factor promotes survival of new neurons in the adult
hippocampus. Neurobiology of Disease, 26(1), 47–55.
52. Manni, L., Rocco, M. L., Bianchi, P., Soligo, M., Guaragna,
M., Barbar, S. P., et al. (2013). Nerve growth factor: basic
studies and possible therapeutic applications. Growth Factors,
31(4), 115–22.
53. Kurata, S., Goto, T., Gunjigake, K. K., Kataoka, S., Kuroishi,
N. K., Ono, K., et al. (2013). Nerve growth factor involves
mutual interaction between neurons and satellite glial cells in
the rat trigeminal ganglion. Acta Histochem Cytochem, 46(2),
65–73.
54. Chen, J., Lee, C. T., Errico, S. L., Becker, K. G., & Freed, W. J.
(2007). Increases in expression of 14-3-3 eta and 14-3-3 zeta tran-
s c r i p t s du r ing neu rop ro t ec t i on induced by de l t a9 -
tetrahydrocannabinol in AF5 cells. Journal of Neuroscience
Research, 85(8), 1724–33.
55. Bonner, H. P., Concannon, C. G., Bonner, C., Woods, I., Ward, M.
W., & Prehn, J. H. (2010). Differential expression patterns of Puma
and Hsp70 following proteasomal stress in the hippocampus are key
determinants of neuronal vulnerability. Journal of Neurochemistry,
114(2), 606–16.
56. Sakurai, M., Ayukawa, K., Setsuie, R., Nishikawa, K., Hara,
Y., Ohashi, H., et al. (2006). Ubiquitin C-terminal hydrolase
L1 regulates the morphology of neural progenitor cells and
modulates their differentiation. Journal of Cell Science,
119(Pt 1), 162–71.
Stem Cell Rev and Rep (2015) 11:288–297 297
Author's personal copy
